Comparison of magnesium status using X-ray dispersion analysis following magnesium oxide and magnesium citrate treatment of healthy subjects

Magnesium Research

Volumn 25, Issue 1, 2012, Pages 28-39

  Shechter, Michael ^a,b   Saad, Tomer ^a,b   Shechter, Alon ^a,b   Koren Morag, Nira ^b   Silver, Burton B ^c   Matetzky, Shlomi ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Intra Cellular Diagnostics Inc   (United States)

Author keywords

Endothelium; Heart disease; Hypertension; Magnesium; Nutrition; Platelets

Indexed keywords

ADRENALIN; CITRIC ACID; DIASPORAL; ELECTROLYTE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; MAGNESIUM CITRATE; MAGNESIUM OXIDE; MAGNOX 520; ORGANOMETALLIC COMPOUND; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD; BLOOD CELL COUNT; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSPNEA; ELECTROLYTE BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HEART PALPITATION; HEART RATE; HEARTBURN; HEAT SENSATION; HUMAN; LEG EDEMA; LEG PAIN; LIPID METABOLISM; LIVER FUNCTION TEST; MAGNESIUM BLOOD LEVEL; MAGNESIUM DEFICIENCY; MALE; METABOLISM; MIDDLE AGED; NAUSEA; NON SPECIFIC CHEST PAIN; NORMAL HUMAN; ORTHOPNEA; PAROXYSMAL DYSPNEA; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SELF REPORT; SIDE EFFECT; THORAX PAIN; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT DURATION; VOMITING; WEAKNESS; X RAY; XEROSTOMIA;

ADULT; AGED; CHOLESTEROL, LDL; CITRIC ACID; FEMALE; HUMANS; LIPID METABOLISM; MAGNESIUM; MAGNESIUM OXIDE; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PLATELET AGGREGATION;

EID: 84860187534     PISSN: 09531424     EISSN: 19524021     Source Type: Journal    
DOI: 10.1684/mrh.2012.0305     Document Type: Article

References (50)

1. Shechter M. Magnesium and cardiovascular system. Magnes Res 2010; 23: 60-72.
2. Shechter M, Kaplinsky E, Rabinowitz B. The rationale of magnesium supplementation in acute myocardial infarction. A review of the literature. Arch Intern Med 1992; 152: 2189-96.
3. Ryzen E, Elkayam U, Rude RK. Low blood mononuclear cell magnesium content in intensive cardiac care unit patients. Am Heart J 1986; 111: 475-80.
4. Reinhart RA. Magnesium metabolism. Arch Intern Med 1988; 148: 2415-20.
5. Shechter M. Does Magnesium have a Role in the Treatment of Patients with Coronary Artery Disease? Am J Cardiovasc Drugs 2003; 3: 231-9.
6. Dong JY, Xun P, He K, Qin LQ. Magnesium intake and risk of type 2 diabetes. Meta-analysis of prospective cohort studies. Diabetes Care 2011; 34: 2116-22.
7. He K, Liu K, Daviglus ML, Morris SJ, Loria CM, Van Horn L, Jacobs Jr. DR, Savage PJ. Magnesium Intake and Incidence of Metabolic Syndrome Among Young Adults. Circulation 2006; 113: 1675-82.
8. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998; 136: 480-90.
9. Ford ES. Serum magnesium and ischemic heart disease: findings from national sample of US adults. Int J Epidemiol 1999; 28: 645-51.
10. Abbott RD, Ando F, Masak KH, Tung KH, Rodriguez BL, Petrovitch H, Yano K, Curb JD. Dietary Magnesium Intake and the Future Risk of Coronary Heart Disease (The Honolulu Heart Program). Am J Cardiol 2003; 92: 665-9.
11. Amighi J, Sabeti S, Schlager O, Mlekusch W, Exner M, Lalouschek W, Ahmadi R, Minar E, Schillinger M. Low Serum Magnesium Predicts Neurological Events in Patients With Advanced Atherosclerosis. Stroke 2004; 35: 22-7.
12. Dickens BF, Weglicki WB, Li YS, Mak IT. Magnesium deficiency in vitro enhances free radicalinduced intracellular oxidation and cytotoxicity in endothelial cells. FEBS 1992; 311: 187-91.
13. Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am Heart J 1984; 108: 188-93.
14. Rasmussen HS, Meier K, Larsen OG, Larsen J. Hemodynamic effects of intravenous administered magnesium in patients with ischemic heart disease. Int J Cardiol 1988; 11: 824-8.
15. Pokan R, Hofmann P, von Duvillard SP, Smekal G, Wonisch M, Lettner K, Schmid P, Shechter M, Silver B, Bachl N. Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients. Br J Sports Med 2006; 40: 773-8.
16. Arsenian MA. Magnesium and cardiovascular disease. Prog Cardiovasc Dis 1993; 35: 271-310.
17. Rasmussen HS, Aurup P, Goldstein K, et al. Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. Arch Intern Med 1989; 149: 1050-3.
18. Shechter M, Sharir M, Paul Labrador M, Forrester J, Silver B, Bairey Merz CN. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000; 102: 2353-8.
19. Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD, Dwyer JH, Shah PK, Kaul S. Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol 1999; 84: 152-6.
20. Rukshin V, Azarbal B, Shah PK, Tsang VT, Shechter M, Finkelstein A, Cercek B, Kaul S. Intravenous magnesium in experimental stent thrombosis in swine. Arterioscler Thromb Vasc Biol 2001; 21: 1544-9.
21. Seelig MS, Rosanoff A. The magnesium factor. New York:Avery Publishers, 2003.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130(6): 461-70.
23. Haigney MC, Silver B, Tanglao E, Silverman HS, Hill JD, Shapiro E, Gerstenblith G, Schulman SP. Noninvasive measurement of tissue magnesium and correlation with cardiac levels. Circulation 1995; 92: 2190-7.
24. Silver BB. Development of cellular magnesium nano-analysis in treatment of clinical magnesium deficiency. J Am Coll Nutr 2004; 23: 732S-7S.
25. McBride BF, Min B, Kluger J, Guertin D, Henyan NN, Coleman CI, Silver BB, White CM. An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. Ann Noninvasive Electrocardiol 2006; 11: 163-9.
26. Baker WL, Kluger J, White CM, Dale KM, Silver BB, Coleman CI. Effect of magnesium Llactate on blood pressure in patients with an implantable cardioverter defibrillator. Ann Pharmacother 2009; 43: 569-76.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
28. Shechter M, Bairey Merz CN, Stuehlinger HG, Slany J, Pachinger O, Rabinowitz B. Oral magnesium supplementation improves exercise duration and quality of life in patients with coronary artery disease. Am J Cardiol 2003; 91: 517-21.
29. Seelig MS. The requirement of magnesium by the normal adult. Am J Clin Nutr 1964; 6: 342-90.
30. Centers for Disease Control and Prevention. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase I, 1988-91. Advance data from vital and health statistics; no 258. Hyattsville, MD: National Center for Health Statistics, 1994:1-28.
31. Lowenstein FW, Stanton MF. Serum magnesium levels in the United States, 1971-1974. J Am Coll Nutr 1986; 5(4): 399-414.
32. Seelig MS. Cardiovascular consequences of magnesium deficiency and loss: Pathogenesis, prevalence and manifestations- magnesium and chloride loss in refractory potassium repletion. Am J Cardiol 1989; 63: 4G-21G.
33. Lichton IJ. Dietary intake levels of requirements of Mg and Ca for different segments of the US population. Magnesium 1989; 8: 117-23.
34. Whang R, Flink E, Dyckner T, Wester PO, Aikawa JK, Ryan MP. Magnesium depletion as a cause of refractory potassium repletion. Arch Intern Med 1985; 145: 1686-9.
35. Rukshin V, Shah PK, Cercek B, Finkelstein A, Tsang V, Kaul S. Comparative antithrombotic effects of magnesium sulfate and platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis. Circulation 2002; 105: 1970-5.
36. Frandsen NJ, Winther K, Pedersen F, Christiansen I, McNair P. Magnesium and platelet function: In vivo influence on aggregation and alpha-granule release in healthy volunteers. Magnesium Bull 1995; 17: 37-40.
37. Hwang DL, Yen CF, Nadler JL. Effect of extracellular magnesium on platelet activation and intracellular calcium mobilization. Am J Hypertens 1992; 5: 700-6.
38. Born GVR, Cross GP. Effect of inorganic ions and plasma proteins on the aggregation of blood platelets by adenosine diphosphate. J Physiol 1964; 170: 397-414.
39. Rukshin V, Santos R, Gheorghiu M, Shah PK, Kar S, Padmanabhan S, Azarbal B, Tsang VT, Makkar R, Samuels B, Lepor N, Geft I, Tabak S, Khorsandhi M, Buchbinder N, Eigler N, Cercek B, Hodgson K, Kaul S. A prospective, nonrandomized, open-labeled pilot study investigating the use of magnesium in patients undergoing nonacute percutaneous coronary intervention with stent implantation. J Cardiovasc Pharmacol Ther 2003; 8: 193-200.
40. Davis WH, Leary WP, Reyes AH. Monotherapy with magnesium increases abnormally low high density lipoprotein cholesterol: A clinical assay. Curr Ther Res 1984; 36: 341-4.
41. Nielsen FH, Johnson LK, Zeng H. Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep. Magnes Res 2010; 23: 158-68.
42. King DE, Mainous AG 3rd, Geesey ME, Ellis T. Magnesium intake and serum C-reactive protein levels in children. Magnes Res 2007; 20: 32-6.
43. Lindberg JS, Zobitz MM, Poindexter JR, Pak CY. Magnesium bioavailability from magnesium citrate and magnesium oxide. JAmColl Nutr 1990; 9: 48-55.
44. Muhlbauer B, Schwenk M, Coram WM, Antonin KH, Etienne P, Bieck PR, Douglas FL. Magnesium-Laspartate- HCL and magnesium-oxide: bioavailability in healthy volunteers. Eur J Clin Pharmacol 1991; 40: 437-8.
45. Altura BT, Wilimzig C, Trnovec T, Nyulassy S, Altura BM. Comparative effects of a Mg-enriched diet and different orally administered magnesium oxide preparations on ionized Mg, Mg metabolism and electrolytes in serum of human volunteers. J Am Coll Nutr 1994; 13: 447-54.
46. Ross JR, Dargan PI, Jones AL, Kostrzewski A. A case of hypomagnesaemia due to malabsorption, unresponsive to oral administration of magnesium glycerophosphate, but responsive to oral magnesium oxide supplementation. Gut 2001; 48: 857-8.
47. Furia TE. Sequestrants in Foods. CRC Handbook of Food Additives. Cleveland CRC Press, Boca Raten, FL, USA. 2nd ed. Chapter 6, 1972.
48. Elin RJ. Status of the determination of magnesium in mononuclear blood cells in humans. Magnesium 1988; 7: 300-5.
49. Haigney MC, Wei S, Kaab S, Griffiths E, Berger R, Tunin R, Kass D, Fisher WG, Silver B, Silverman H. Loss of cardiac magnesium in experimental heart failure prolongs and destabilizes repolarization in dogs. J Am Coll Cardiol 1998; 31: 701-6.
50. Cohen L. Physiologic assessment of magnesium status in humans: a combination of load retention and renal excretion. IMAJ 2000; 2: 938-9.